IN THE SUPERIOR COURT OF THE STATE OF DELAWARE
VENATOR MATERIALS PLC, ) ) Plaintiff, ) ) v. ) ) C.A. No.: N19C-05-117 EMD CCLD TRONOX LIMITED, ) ) Defendant. ) )
Submitted: October 8, 2021 Decided: January 7, 2022
Upon Plaintiff’s Motions in Limine GRANTED, in part, and DENIED, in part
David E. Ross, Esquire, Garrett B. Moritz, Esquire, S. Michael Sirkin, Esquire, Adam D. Gold, Esquire, S. Reiko Rogozen, Esquire, Ross Aronstam & Moritz LLP, Wilmington, Delaware, Attorneys for Plaintiff/Counterclaim Defendant Venator Materials Plc.
Patricia A. Winston, Esquire, Barnaby Grzaslewicz, Esquire, Morris James LLP, Wilmington, Delaware, Glen Silverstein, Esquire, Michael J. Tiffany, Esquire, Stephanie L. Gase, Esquire, Daniel A. Johnson, Esquire, Leader Berkon Colao & Silverstein LLP, New York, New York, Attorneys for Defendant/Counterclaim Plaintiff Tronox Limited.
DAVIS, J.
I. INTRODUCTION
This is a breach of contract action assigned to the Complex Commercial Litigation
Division of the Court. Venator Materials Plc (“Venator”) and Tronox Limited (“Tronox”) both
assert claims arising out of a preliminary agreement to negotiate a potential sale of a chemical
plant by Tronox to Venator. Now before the Court are four motions in limine filed by Venator:
(i) motion to exclude evidence relating to unrelated securities lawsuits (the “Securities Lawsuits
Motion”); (ii) motion to preclude portions of Richard Feinstein’s expert testimony (the “Feinstein Motion”); (iii) motion to exclude certain evidence related to the background of Kevin
Arquit (the “Arquit Motion”); and (iv) motion to preclude Tronox from testifying regarding
Tronox’s position regarding the July 14 Agreement (the “July 14 Agreement Motion”).
For the reasons set forth below, the Arquit Motion and the Securities Lawsuits Motion
are GRANTED. In addition, the Feinstein Motion and the July 14 Agreement Motion are
DENIED.
II. FACTS
Tronox and Venator are both TiO2 manufacturers.1 In February 2017, Tronox agreed to
acquire Cristal, another participant in the TiO2 market.2 The FTC objected to the Tronox-Cristal
merger on the grounds that it would lead to an unacceptable level of market concentration that
was presumptively anticompetitive.3 In July 2018, the FTC sought an injunction to prevent the
merger from closing before a decision in the administrative proceeding.4 The injunction was
granted after a hearing in August 2018, finding that the merger would likely “lead to
anticompetitive behavior among the industry’s remaining players.”5
Tronox attempted to address the FTC’s concerns about market concentration by reducing
its own market share.6 In July 2018, Tronox and Venator entered into a preliminary agreement
to negotiate a potential sale of a chemical plant by Tronox to Venator (the “July Agreement”).7
Because Venator was an existing market participant, the FTC would likely require Venator to
divest some of its own assets before the FTC would approve the transaction.8 The July
1 Tronox’s Opp. to Venator’s Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 3 (D.I. No. 139). 2 Venator’s Opening Br. in Supp. of Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 1 (D.I. No. 128). 3 Id. at 1–2. 4 Id. at 2. 5 Id. 6 Tronox’s Opp. to Venator’s Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 4. 7 Venator’s Opening Br. in Supp. of Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 3. 8 Tronox’s Opp. to Venator’s Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 4.
2 Agreement therefore included a “hell-or-high water” provision, which required Venator to take
“all actions necessary” to obtain antitrust approval from the FTC.9 Venator therefore agreed to
take all actions necessary to address any concerns that the FTC might raise.
Problems arose as Tronox and Venator negotiated the final stock purchase agreement (the
“SPA”). According to Tronox, Venator refused to include the previous “hell-or-high water”
provision in the SPA. Instead, the only step that Venator was willing to take was to divest its
joint venture interest in the Louisiana Pigment Company to Kronos—an existing joint venture
partner.10 Venator’s proposal was problematic because Kronos was already a major participant
in the TiO2 market. The FTC rejected Venator’s proposal when Venator submitted it for FTC
approval because it failed to address the concerns about reduced market participants and market
concentration.11 As a result, Tronox and Venator never entered the final SPA, and Tronox was
required to sell the chemical plant to another buyer at a lower price.
Each party accuses the other of violating the July Agreement. Tronox alleges that
Venator breached its “hell-or-high water” commitment by insisting on taking only one action to
address the FTC’s antitrust concerns (i.e., the sale of its LPC interest to Kronos).12 Venator
claims that Tronox failed to pay a “Break Fee” that had become due under the July Agreement.13
III. APPLICABLE LAW
To be admissible, evidence must be relevant, meaning it has “any tendency to make the
existence of any fact that is of consequence to the determination of the action more probable or
less probable than it would be without the evidence.”14 To determine relevance, the Court must
9 Id. 10 Id. at 4–5. 11 Id. at 5. 12 Id. 13 Compl. at ¶ 1. 14 D.R.E. 401.
3 examine the purpose for which evidence is offered and whether it is of consequence to the action
and advances the likelihood of asserted facts.15 Under D.R.E. 403, the Court may exclude
evidence where the danger of undue prejudice substantially outweighs its probative value.16
Probative value concerns “the tendency of the evidence to establish the proposition that it is
offered to prove.”17
The admissibility of expert testimony is governed by Delaware Rules of Evidence 702
(“Rule 702”). Rule 702 provides that:
If scientific, technical or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training or education may testify thereto in the form of an opinion or otherwise, if (1) the testimony is based upon sufficient facts or data, (2) the testimony is the product of reliable principles and methods, and (3) the witness has applied the principles and methods reliably to the facts of the case.18
When applying Rule 702, Delaware Courts have adopted the U.S. Supreme Court’s
holdings in Daubert v. Merrell Dow Pharmaceuticals.19 Daubert requires the trial judge to act
as gatekeeper and determine whether the expert testimony is relevant and reliable and whether it
will assist the trier of fact.20 The Delaware Supreme has adopted a five-part test for trial courts
to consider when determining the admissibility of scientific or technical testimony. The trial
court must decide whether:
(i) the witness is qualified as an expert by knowledge, skill, experience, training or education; (ii) the evidence is relevant and reliable; (iii) the expert’s opinion is based upon information reasonably relied upon by experts in the particular field; (iv) the expert testimony will assist the trier of fact to understand the evidence or to
15 Sheehan v. Oblates of St. Francis de Sales, 15 A.3d 1247, 1254 (Del. 2011). 16 D.R.E. 403. 17 Getz v.
Free access — add to your briefcase to read the full text and ask questions with AI
IN THE SUPERIOR COURT OF THE STATE OF DELAWARE
VENATOR MATERIALS PLC, ) ) Plaintiff, ) ) v. ) ) C.A. No.: N19C-05-117 EMD CCLD TRONOX LIMITED, ) ) Defendant. ) )
Submitted: October 8, 2021 Decided: January 7, 2022
Upon Plaintiff’s Motions in Limine GRANTED, in part, and DENIED, in part
David E. Ross, Esquire, Garrett B. Moritz, Esquire, S. Michael Sirkin, Esquire, Adam D. Gold, Esquire, S. Reiko Rogozen, Esquire, Ross Aronstam & Moritz LLP, Wilmington, Delaware, Attorneys for Plaintiff/Counterclaim Defendant Venator Materials Plc.
Patricia A. Winston, Esquire, Barnaby Grzaslewicz, Esquire, Morris James LLP, Wilmington, Delaware, Glen Silverstein, Esquire, Michael J. Tiffany, Esquire, Stephanie L. Gase, Esquire, Daniel A. Johnson, Esquire, Leader Berkon Colao & Silverstein LLP, New York, New York, Attorneys for Defendant/Counterclaim Plaintiff Tronox Limited.
DAVIS, J.
I. INTRODUCTION
This is a breach of contract action assigned to the Complex Commercial Litigation
Division of the Court. Venator Materials Plc (“Venator”) and Tronox Limited (“Tronox”) both
assert claims arising out of a preliminary agreement to negotiate a potential sale of a chemical
plant by Tronox to Venator. Now before the Court are four motions in limine filed by Venator:
(i) motion to exclude evidence relating to unrelated securities lawsuits (the “Securities Lawsuits
Motion”); (ii) motion to preclude portions of Richard Feinstein’s expert testimony (the “Feinstein Motion”); (iii) motion to exclude certain evidence related to the background of Kevin
Arquit (the “Arquit Motion”); and (iv) motion to preclude Tronox from testifying regarding
Tronox’s position regarding the July 14 Agreement (the “July 14 Agreement Motion”).
For the reasons set forth below, the Arquit Motion and the Securities Lawsuits Motion
are GRANTED. In addition, the Feinstein Motion and the July 14 Agreement Motion are
DENIED.
II. FACTS
Tronox and Venator are both TiO2 manufacturers.1 In February 2017, Tronox agreed to
acquire Cristal, another participant in the TiO2 market.2 The FTC objected to the Tronox-Cristal
merger on the grounds that it would lead to an unacceptable level of market concentration that
was presumptively anticompetitive.3 In July 2018, the FTC sought an injunction to prevent the
merger from closing before a decision in the administrative proceeding.4 The injunction was
granted after a hearing in August 2018, finding that the merger would likely “lead to
anticompetitive behavior among the industry’s remaining players.”5
Tronox attempted to address the FTC’s concerns about market concentration by reducing
its own market share.6 In July 2018, Tronox and Venator entered into a preliminary agreement
to negotiate a potential sale of a chemical plant by Tronox to Venator (the “July Agreement”).7
Because Venator was an existing market participant, the FTC would likely require Venator to
divest some of its own assets before the FTC would approve the transaction.8 The July
1 Tronox’s Opp. to Venator’s Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 3 (D.I. No. 139). 2 Venator’s Opening Br. in Supp. of Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 1 (D.I. No. 128). 3 Id. at 1–2. 4 Id. at 2. 5 Id. 6 Tronox’s Opp. to Venator’s Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 4. 7 Venator’s Opening Br. in Supp. of Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 3. 8 Tronox’s Opp. to Venator’s Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 4.
2 Agreement therefore included a “hell-or-high water” provision, which required Venator to take
“all actions necessary” to obtain antitrust approval from the FTC.9 Venator therefore agreed to
take all actions necessary to address any concerns that the FTC might raise.
Problems arose as Tronox and Venator negotiated the final stock purchase agreement (the
“SPA”). According to Tronox, Venator refused to include the previous “hell-or-high water”
provision in the SPA. Instead, the only step that Venator was willing to take was to divest its
joint venture interest in the Louisiana Pigment Company to Kronos—an existing joint venture
partner.10 Venator’s proposal was problematic because Kronos was already a major participant
in the TiO2 market. The FTC rejected Venator’s proposal when Venator submitted it for FTC
approval because it failed to address the concerns about reduced market participants and market
concentration.11 As a result, Tronox and Venator never entered the final SPA, and Tronox was
required to sell the chemical plant to another buyer at a lower price.
Each party accuses the other of violating the July Agreement. Tronox alleges that
Venator breached its “hell-or-high water” commitment by insisting on taking only one action to
address the FTC’s antitrust concerns (i.e., the sale of its LPC interest to Kronos).12 Venator
claims that Tronox failed to pay a “Break Fee” that had become due under the July Agreement.13
III. APPLICABLE LAW
To be admissible, evidence must be relevant, meaning it has “any tendency to make the
existence of any fact that is of consequence to the determination of the action more probable or
less probable than it would be without the evidence.”14 To determine relevance, the Court must
9 Id. 10 Id. at 4–5. 11 Id. at 5. 12 Id. 13 Compl. at ¶ 1. 14 D.R.E. 401.
3 examine the purpose for which evidence is offered and whether it is of consequence to the action
and advances the likelihood of asserted facts.15 Under D.R.E. 403, the Court may exclude
evidence where the danger of undue prejudice substantially outweighs its probative value.16
Probative value concerns “the tendency of the evidence to establish the proposition that it is
offered to prove.”17
The admissibility of expert testimony is governed by Delaware Rules of Evidence 702
(“Rule 702”). Rule 702 provides that:
If scientific, technical or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training or education may testify thereto in the form of an opinion or otherwise, if (1) the testimony is based upon sufficient facts or data, (2) the testimony is the product of reliable principles and methods, and (3) the witness has applied the principles and methods reliably to the facts of the case.18
When applying Rule 702, Delaware Courts have adopted the U.S. Supreme Court’s
holdings in Daubert v. Merrell Dow Pharmaceuticals.19 Daubert requires the trial judge to act
as gatekeeper and determine whether the expert testimony is relevant and reliable and whether it
will assist the trier of fact.20 The Delaware Supreme has adopted a five-part test for trial courts
to consider when determining the admissibility of scientific or technical testimony. The trial
court must decide whether:
(i) the witness is qualified as an expert by knowledge, skill, experience, training or education; (ii) the evidence is relevant and reliable; (iii) the expert’s opinion is based upon information reasonably relied upon by experts in the particular field; (iv) the expert testimony will assist the trier of fact to understand the evidence or to
15 Sheehan v. Oblates of St. Francis de Sales, 15 A.3d 1247, 1254 (Del. 2011). 16 D.R.E. 403. 17 Getz v. State, 538 A.2d 726, 731 (Del.1988). 18 D.R.E. 702. 19 See Bowen v. E.I. DuPont de Nemours & Co., Inc., 906 A.2d 787, 794 (Del. 2006) (“Though the United States Supreme Court’s interpretations of F.R.E. 702 in Daubert and Kumho are only binding upon federal courts, this Court has expressly adopted their holdings as correct interpretations of D.R.E. 702”) (internal citations omitted). 20 See id; see also Daubert . Merrell Dow Pharmaceuticals, 509 U.S. 579, 582 (1993) (internal citations omitted).
4 determine a fact in issue; and (v) the expert testimony will not create unfair prejudice or confuse or mislead the jury.21
IV. THE MOTIONS
A. THE JULY 14 AGREEMENT MOTION
Venator seeks to prove that Tronox violated the “Exclusivity Period” of the July
Agreement. Specifically, Venator alleges that Tronox’s CEO secretly communicated with a
banker advising another potential purchaser about the transaction.22 Venator sought information
about this subject at the deposition of Jeff Neuman, Tronox’s general counsel. However, Tronox
blocked Mr. Neuman from testifying whether, as he understood the July Agreement:
1. Tronox was “permitted to have discussions with parties other than Venator regarding an alternative transaction.”
2. “During the exclusivity period,” Tronox “could . . . communicate about Ashtabula with advisers of other potential bidders.”
3. Tronox could tell “another potential bidder or its advisers that if the deal with Venator failed, Tronox would come back with that other bidder to do a deal.”
4. Tronox could “ask its employees and advisers to shift their focus away from negotiating an SPA with Venator towards preparing to negotiate an SPA with another party.23
Instead, Tronox either instructed Mr. Neuman to testify regarding “Tronox’s position” on the
July Agreement or, in some cases, prevented him from answering at all.24
Venator argues that testimony regarding “Tronox’s position” is irrelevant because it is
neither probative nor material to any issue in the case. Instead, Venator contends that Tronox’s
position is simply its “litigation contentions,” which have no bearing on the events in the case or
21 Cunningham v. McDonald, 689 A.2d 1190, 1193 (Del. 1997). 22 Venator’s Mot. to Prelude Tronox From Testifying Regarding “Tronox’s Position” Regarding the July 14 Agreement at 1 (D.I. No. 129). 23 Id. at 3. 24 Id. at 4.
5 the meaning of the July Agreement.25 Venator adds that testimony regarding “Tronox’s
position” would be highly prejudicial to Venator because it “effectively allows Tronox to offer
testimony to support its claims while preventing Venator from testing how those claims compare
to the actual facts.”26
In response, Tronox argues that its position are not merely arguments but rather historical
facts that bear on the issues in the case. Tronox points out that a key issue in this case is how the
parties understood the contractual terms as they negotiated them.27 Additionally, Tronox argues
that any relevancy challenge is better resolve during trial, once the Court has heard the questions
being asked and seen the evidence being presented.28
B. THE FEINSTEIN MOTION
Tronox seeks to have Richard Feinstein testify as an expert witness. Mr. Feinstein is a
lawyer who formerly led the FTC’s Bureau of Competition; however, Mr. Feinstein is not an
economist and never participated in economic modeling at the FTC. Tronox offers Mr. Feinstein
on the issue of whether “the FTC would have approved Venator as a buyer” of the chemical
plant if Venator had proposed divesting a specific asset to a new market entrant.29 Mr.
Feinstein’s opinion is based on his “years of experience with the FTC.”30 At deposition,
Feinstein acknowledged that he himself did not perform any economic modeling or economic
analysis in reaching his opinion.31
25 Id. at 5. 26 Id. at 5–6. 27 Tronox’s Opp. to Venator’s Mot. to Preclude Tronox from Testifying Regarding “Tronox’s Position” Regarding the July 14 Agreement at 1–4 (D.I. No. 132). 28 Id. at 1. 29 Venator’s Opening Br. in Supp. of Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 1. 30 Id. at 5. 31 Id. at 4–5.
6 Venator argues that Mr. Feinstein’s testimony should be excluded because (i) Mr.
Feinstein lacks sufficient expertise to offer this opinion, and (ii) Mr. Feinstein does not base his
opinion on a reliable methodology. The thrust of Venator’s argument is that the FTC reviews
transactions to assess their likely effects on competition, which involves extensive economic
analysis.32 Venator notes that Mr. Feinstein did no such analysis and lacks any expertise in
economics. Therefore, Venator contends that Mr. Feinstein is not able to opine on whether the
FTC would have approved a transaction involving Venator.
In response, Tronox points out that Mr. Feinstein has extensive experience in reviewing
mergers and divestitures for regulatory approval and in fact drafted official FTC guidelines on
these topics.33 Tronox adds that Mr. Feinstein’s opinion expressly draws upon a record of
economic facts and analyses.34 Tronox argues that any further challenges go to weight, rather
than to admissibility because Mr. Feinstein otherwise is competent to testify as an expert.35
C. THE ARQUIT MOTION
Venator intends to call Kevin Arquit as an expert witness. Mr. Arquit is an antitrust
lawyer who formerly served as the Director of the Bureau of Competition at the FTC. Venator
seeks to exclude examination or evidence about three subjects that Tronox explored at his
deposition.36 First, Mr. Arquit was subject to a Daubert challenge in a prior case, but the case
settled before the court ruled on it. Second, Mr. Arquit was a plaintiff in a confidential
arbitration in which the defendant asserted a counterclaim. Mr. Arquit explained that the matter
was not a claim by a former client, that the arbitration had no relation to antitrust, and that he
32 Id. at 2–3. 33 Tronox’s Opp. to Venator’s Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 1. 34 Id. at 2–3. 35 Id. at 9–10. 36 Venator’s Motion to Preclude Examination or Evidence Related to Kevin Arquit at 1–3 (D.I. No. 127).
7 was not found to have any personal liability. Third, a former client of Mr. Arquit’s former law
firm brought a malpractice lawsuit against the firm about 20 years ago. The lawsuit alleged that
the firm had improperly delegated work to junior lawyers with limited experience. Mr. Arquit
was not named as a defendant and had left the firm before the lawsuit was filed. He does not
know the terms on which the firm resolved the case.
Venator argues that evidence of these three actions is irrelevant because none of the
matters is probative with respect to Mr. Arquit, his opinion, or the events of this case.37 Venator
adds that the evidence would be unduly prejudicial even if it possessed any probative value.38
Tronox does not oppose Venator’s motion.39 Tronox agrees that the confidential arbitration and
malpractice lawsuits are irrelevant. Furthermore, Tronox agrees that the prior Daubert challenge
is irrelevant and will not question him on it, “[u]nless Venator affirmatively puts the Daubert
motion at issue.”40
D. THE SECURITIES LAWSUITS MOTION
Venator is the defendant in securities class actions pending in Texas federal court and the
state courts of Texas and New York. The class actions relate to alleged disclosure violations in
connection with Venator’s initial public offering in August 2017 and secondary public offering
in December 2017.41 Certain witnesses who may testify at trial have also been named as
defendants in the securities lawsuits.
Venator argues that evidence relating to the securities lawsuits would be irrelevant to the
current case and unduly prejudicial even if it had some relevance.42 Tronox “generally agrees
37 Id. at 3–6. 38 Id. 39 Tronox’s Response to Venator’s Mot. to Preclude Examinations or Evidence Related to Kevin Arquit at 1–2 (D.I. No. 134). 40 Id. at 1. 41 Venator’s Mot. to Exclude Evidence Relating to Unrelated Securities Lawsuits at 1–2 (D.I. No. 130). 42 Id. at 3–6.
8 with Venator’s conclusion that such testimony is inadmissible at this time” and will not elicit
testimony about the securities lawsuits.43 However, Tronox cautions that Venator may put the
good character of its witnesses into issue during trial, thereby opening the door to questioning
about their credibility and character for truthfulness.44 Tronox may then ask the Court to
reconsider this issue and allow cross-examination about the securities lawsuits.45
V. DISCUSSION
Tronox does not oppose the Arquit Motion or the Securities Lawsuits Motion. The Court
will, therefore, grant these motions. However, the Court may revisit the issues raised in the
motions if evidence adduced at trial makes them relevant.
The Court is denying the Feinstein Motion. Mr. Feinstein is qualified to testify as to
whether the FTC would have approved Venator as a buyer of the chemical plant. Mr. Feinstein
has over 40 years of antitrust experience and extensive experience in reviewing mergers and
divestitures for regulatory approval.46 As Director of the FTC’s Bureau of Competition, Mr.
Feinstein oversaw approximately 80 enforcement actions.47 Furthermore, Mr. Feinstein based
his opinion on documentary evidence, FTC practices and procedures, and an economic analysis
of market concentration.48 Venator’s arguments for excluding Mr. Feinstein ultimately go to the
weight of his testimony and not to his qualifications as an expert. Venator is free to highlight the
weaknesses of Feinstein’s analysis on cross examination, but not to exclude his testimony
altogether.49
43 Tronox’s Response to Venator’s Mot. to Exclude Evidence Relating to Unrelated Securities Lawsuits at 2 (D.I. No. 133). 44 Id. 45 Id. 46 Tronox’s Opp. to Venator’s Mot. to Preclude Portions of Richard Feinstein’s Expert Testimony at 1. 47 Id. 48 Id. at 2. 49 See Estate of Valdez v. BNSF Ry. Co., 2020 WL 7365800, at *5 (Del. Super. Dec. 15, 2020) (“Once the trial court has determined that a witness is competent to testify as an expert, challenges to the expert’s skill or knowledge go to
9 The Court will also deny the July 14 Agreement Motion. The Court finds that it would
be premature to rule upon the relevancy and potential prejudice of this topic. Currently, the
Court has few details on what “Tronox’s position” even is or what role it may play in the trial.
Furthermore, the Court has not heard what questions the parties will ask to the witnesses or seen
the evidence that will contextualize those questions. In short, the issues of relevancy and
prejudice that Venator raised are better resolved at trial, if necessary.50
VI. CONCLUSION
The Arquit Motion and the Securities Lawsuits Motion are GRANTED. The Feinstein
Motion and the July 14 Agreement Motion are DENIED.
IT IS SO ORDERED
Dated: January 7, 2022 Wilmington, Delaware
/s/ Eric M. Davis Eric M. Davis, Judge
cc: File&ServeExpress
the weight to be accorded the expert testimony rather than its admissibility.”) (quoting Perry v. Berkley, 996 A.2d 1262, 1270–71 (Del. 2010)). 50 See Evolved Wireless, LLC v. Apple Inc., 2019 WL 1100471, at *1 (D. Del. Mar. 7, 2019) (“A motion in limine is appropriate for ‘evidentiary submissions that clearly ought not be presented to the jury because they clearly would be inadmissible for any purpose.’ In other instances, it is necessary to defer ruling until during trial, when the judge can better estimate the impact of the evidence.”) (internal citations omitted).